214 related articles for article (PubMed ID: 17035318)
1. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity.
Thorner AR; Lemckert AA; Goudsmit J; Lynch DM; Ewald BA; Denholtz M; Havenga MJ; Barouch DH
J Virol; 2006 Dec; 80(24):12009-16. PubMed ID: 17035318
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity.
Lemckert AA; Sumida SM; Holterman L; Vogels R; Truitt DM; Lynch DM; Nanda A; Ewald BA; Gorgone DA; Lifton MA; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2005 Aug; 79(15):9694-701. PubMed ID: 16014931
[TBL] [Abstract][Full Text] [Related]
3. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D.
Abbink P; Lemckert AA; Ewald BA; Lynch DM; Denholtz M; Smits S; Holterman L; Damen I; Vogels R; Thorner AR; O'Brien KL; Carville A; Mansfield KG; Goudsmit J; Havenga MJ; Barouch DH
J Virol; 2007 May; 81(9):4654-63. PubMed ID: 17329340
[TBL] [Abstract][Full Text] [Related]
4. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys.
Nanda A; Lynch DM; Goudsmit J; Lemckert AA; Ewald BA; Sumida SM; Truitt DM; Abbink P; Kishko MG; Gorgone DA; Lifton MA; Shen L; Carville A; Mansfield KG; Havenga MJ; Barouch DH
J Virol; 2005 Nov; 79(22):14161-8. PubMed ID: 16254351
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
Iampietro MJ; Larocca RA; Provine NM; Abbink P; Kang ZH; Bricault CA; Barouch DH
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563285
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.
Ophorst OJ; Radosević K; Havenga MJ; Pau MG; Holterman L; Berkhout B; Goudsmit J; Tsuji M
Infect Immun; 2006 Jan; 74(1):313-20. PubMed ID: 16368986
[TBL] [Abstract][Full Text] [Related]
9. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein.
Sumida SM; Truitt DM; Lemckert AA; Vogels R; Custers JH; Addo MM; Lockman S; Peter T; Peyerl FW; Kishko MG; Jackson SS; Gorgone DA; Lifton MA; Essex M; Walker BD; Goudsmit J; Havenga MJ; Barouch DH
J Immunol; 2005 Jun; 174(11):7179-85. PubMed ID: 15905562
[TBL] [Abstract][Full Text] [Related]
11. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
12. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys.
Liu J; Ewald BA; Lynch DM; Denholtz M; Abbink P; Lemckert AA; Carville A; Mansfield KG; Havenga MJ; Goudsmit J; Barouch DH
J Virol; 2008 May; 82(10):4844-52. PubMed ID: 18337575
[TBL] [Abstract][Full Text] [Related]
13. Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals.
Fuchs JD; Bart PA; Frahm N; Morgan C; Gilbert PB; Kochar N; DeRosa SC; Tomaras GD; Wagner TM; Baden LR; Koblin BA; Rouphael NG; Kalams SA; Keefer MC; Goepfert PA; Sobieszczyk ME; Mayer KH; Swann E; Liao HX; Haynes BF; Graham BS; McElrath MJ;
J AIDS Clin Res; 2015 May; 6(5):. PubMed ID: 26587311
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions.
Bradley RR; Maxfield LF; Lynch DM; Iampietro MJ; Borducchi EN; Barouch DH
J Virol; 2012 Jan; 86(2):1267-72. PubMed ID: 22072746
[TBL] [Abstract][Full Text] [Related]
15. Interaction between hexon and L4-100K determines virus rescue and growth of hexon-chimeric recombinant Ad5 vectors.
Yan J; Dong J; Wu J; Zhu R; Wang Z; Wang B; Wang L; Wang Z; Zhang H; Wu H; Yu B; Kong W; Yu X
Sci Rep; 2016 Mar; 6():22464. PubMed ID: 26934960
[TBL] [Abstract][Full Text] [Related]
16. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
17. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity.
Lemckert AAC; Grimbergen J; Smits S; Hartkoorn E; Holterman L; Berkhout B; Barouch DH; Vogels R; Quax P; Goudsmit J; Havenga MJE
J Gen Virol; 2006 Oct; 87(Pt 10):2891-2899. PubMed ID: 16963747
[TBL] [Abstract][Full Text] [Related]
18. Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon.
Tian X; Su X; Li H; Li X; Zhou Z; Liu W; Zhou R
Virus Res; 2011 Sep; 160(1-2):214-20. PubMed ID: 21740937
[TBL] [Abstract][Full Text] [Related]
19. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity.
Johnson MJ; Petrovas C; Yamamoto T; Lindsay RW; Loré K; Gall JG; Gostick E; Lefebvre F; Cameron MJ; Price DA; Haddad E; Sekaly RP; Seder RA; Koup RA
J Immunol; 2012 Jun; 188(12):6109-18. PubMed ID: 22586038
[TBL] [Abstract][Full Text] [Related]
20. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.
Ophorst OJ; Kostense S; Goudsmit J; De Swart RL; Verhaagh S; Zakhartchouk A; Van Meijer M; Sprangers M; Van Amerongen G; Yüksel S; Osterhaus AD; Havenga MJ
Vaccine; 2004 Aug; 22(23-24):3035-44. PubMed ID: 15297053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
